Acelyrin INC., a United States-based biopharma company, announced on Thursday, June 10, that it has named Patrick (Pat) Machado, JD as its new director.

Machado has over two decades of experience supporting biopharmaceutical organisations from development through commercialisation. Presently, Machado serves on the boards of Adverum Biotechnologies Inc., Turning Point Therapeutics, Chimerix Inc., Roivant Sciences Ltd., Xenon Pharmaceuticals, Turnstone Biologics, and Arcus Biosciences. He has served as a director of Endocyte, Principia Biopharma and Therachon. He has served as director for a total of 15 public and private biotech companies, with roles including chairing boards, audit, and compensation committees.

He was co-founder and has served as chief business and financial officer, and board member of Medivation, Inc. He has also held the position of senior vice president, finance and business development, chief financial officer, and general counsel of Pro-Duct Health Inc. He has also served as division corporate counsel for Chiron Technologies at Chiron Corporation. He started his career in the corporate finance department as an attorney at Morrison and Foerster LLP.